Results 161 to 170 of about 331,966 (252)

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

Biomimetic Macrophage Cell Membrane‐Based Nanoparticles for Effective Treatment of Glioblastoma Through Boron Neutron Capture Therapy Combined With Immunotherapy

Advanced Science, EarlyView.
ABSTRACT Glioblastoma multiforme (GBM) remains largely incurable due to the blood‐brain barrier (BBB) and immunosuppressive microenvironment. While boron neutron capture therapy (BNCT) selectively eradicates tumor cells via 10B(n, α)‐7Li reactions, its clinical potential in GBM is unrealized because of the suboptimal pharmacokinetics of conventional ...
Jiawen Chen, Haoyu You, Hefa Huang, Huihui Chai, Ruize Zhu, Yun Guan, Qisheng Tang, Tianwen Li, Shan Jiang, Houshi Xu, Peng Wang, Yue Wang, Maoyuan Sun, Beining Liu, Zhen Li, Yulai Zeng, Weiqiu Ping, Yanlin Teng, Songlin Yan, Qinghui Li, Long Gu, Tao Sun, Zhifeng Shi   +22 more
wiley   +1 more source

Anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (nAMD): a network meta-analysis. [PDF]

Cochrane Database Syst Rev
Lucenteforte E, Ng SM, Saulle R, Hoad G, Schillinger R, Virgili G.   +5 more
europepmc   +1 more source

Quality Thresholds for Angiogenesis Under Acoustic Manipulation in Engineered Vascular Tissues

Advanced Science, EarlyView.
Defined biological and physical quality thresholds achieved through acoustic manipulation regulate cellular alignment and spatial organization, promoting self‐assembling vasculature, extracellular matrix deposition, and angiogenic responses, thereby establishing critical acoustic patterning requirements for engineered vascular tissue development in ...
Oscar O'Dwyer Lancaster‐Jones, Russell Quinn, Niloofar Khoshdel Rad, Kilian Paul, Andrea Frank, Daniela F. Duarte Campos   +5 more
wiley   +1 more source

EPIRETINAL MACROPHAGE-LIKE CELL ALTERATIONS FOLLOWING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN BRANCH RETINAL VEIN OCCLUSION WITH MACULAR EDEMA: A Retrospective Longitudinal Study. [PDF]

Retina
Bai W, Zhao Y, Zhang YY, Li JY, Zhu SS, Sun C, Wen F, Yao J.   +7 more
europepmc   +1 more source

Multi‐Component Functionalized Bifidobacterium Longum Hydrogel for Multi‐Target Integrated Therapy of Colitis‐Associated Anxiety and Depression

Advanced Science, EarlyView.
A pH/MMP dual‐responsive Bifidobacterium longum (BL) hydrogel (INPs@BL@Gel) functionalized with baicalin, tyrosine, and inulin is constructed. It enables gastric protection, inflammation‐targeted release, and prolonged intestinal colonization. By remodeling gut microbiota, elevating beneficial neuroactive metabolites (homovanillic acid, short‐chain ...
Shuo Zhang, Yujie Zhang, Jiansheng He, Shunlian Li, Qingyan Ma, Qiao Li, Yudan Zhang, Yiyang Wang, Shaobo Ma, Songyan Jin, Chune Li, Xueyong Xie, Hang Zhang, Junze Deng, Xueqin Song, Daocheng Wu, Xiancang Ma, Feng Zhu   +17 more
wiley   +1 more source

Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections. [PDF]

Indian J Ophthalmol
Sagiv RG, Rosenblatt HN, Zamir E, Altarescu A, Ben-Zaken SG, Rotfogel Z.   +5 more
europepmc   +1 more source

Targeting WDR12 Unleashes T‐Cell‐Mediated Antitumor Activity in Melanoma by Destabilizing CD276

Advanced Science, EarlyView.
WDR12 cooperates with the chaperonin subunit CCT7 to maintain CD276 stability on tumor cells, suppressing T‐cell activity and promoting immune escape. SU14813, a small‐molecule WDR12 inhibitor, reduces CD276 stability and relieves CD276‐mediated T‐cell suppression.
Jie Pan, Ruimin Chang, Meng Zhang, Qian Dong, Guanxiong Zhang, Xiang Chen, Mingliang Chen, Lixia Lu, Xiaowei Liang, Yeye Guo, Juan Su   +10 more
wiley   +1 more source

Anti-Vascular Endothelial Growth Factor Crunch Syndrome in Proliferative Diabetic Retinopathy. [PDF]

JCEM Case Rep
Li Z, Zhang Y.
europepmc   +1 more source

DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC

Advanced Science, EarlyView.
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian, Shihang Pu, Zhipeng Xu, Yiheng Ding, Ling Jin, Baochao Li, Qi Li, Xiaohai Xi, Zengjun Wang, Jiajun Xing, Aiming Xu   +10 more
wiley   +1 more source